Similar articles for PMID: 22073242

Year	Number of Results
2003	1
2006	1
2007	1
2008	4
2009	3
2010	3
2011	3
2012	6
2013	6
2014	13
2015	12
2016	12
2017	9
2018	9
2019	9
2020	6
2021	1
2024	0

1

Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer.

London CA, Bear MD, McCleese J, Foley KP, Paalangara R, Inoue T, Ying W, Barsoum J. London CA, et al. PLoS One. 2011;6(11):e27018. doi: 10.1371/journal.pone.0027018. Epub 2011 Nov 3. PLoS One. 2011. PMID: 22073242 Free PMC article.

2

The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.

Lin TY, Bear M, Du Z, Foley KP, Ying W, Barsoum J, London C. Lin TY, et al. Exp Hematol. 2008 Oct;36(10):1266-77. doi: 10.1016/j.exphem.2008.05.001. Epub 2008 Jul 26. Exp Hematol. 2008. PMID: 18657349 Free PMC article.

3

The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines.

McCleese JK, Bear MD, Fossey SL, Mihalek RM, Foley KP, Ying W, Barsoum J, London CA. McCleese JK, et al. Int J Cancer. 2009 Dec 15;125(12):2792-801. doi: 10.1002/ijc.24660. Int J Cancer. 2009. PMID: 19544563 Free article.

4

Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.

Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, Ying W, Barsoum J, Wong KK, Shapiro GI. Shimamura T, et al. Clin Cancer Res. 2012 Sep 15;18(18):4973-85. doi: 10.1158/1078-0432.CCR-11-2967. Epub 2012 Jul 17. Clin Cancer Res. 2012. PMID: 22806877 Free PMC article.

5

Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.

Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, Ye S, Acquaviva J, Ogawa LS, Wada Y, Barsoum J, Koya K. Ying W, et al. Mol Cancer Ther. 2012 Feb;11(2):475-84. doi: 10.1158/1535-7163.MCT-11-0755. Epub 2011 Dec 5. Mol Cancer Ther. 2012. PMID: 22144665

6

Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors.

London CA, Acquaviva J, Smith DL, Sequeira M, Ogawa LS, Gardner HL, Bernabe LF, Bear MD, Bechtel SA, Proia DA. London CA, et al. Clin Cancer Res. 2018 Dec 15;24(24):6396-6407. doi: 10.1158/1078-0432.CCR-18-0703. Epub 2018 Aug 31. Clin Cancer Res. 2018. PMID: 30171047 Free PMC article. Clinical Trial.

7

Investigation of anticancer activities of STA-9090 (ganetespib) as a second generation HSP90 inhibitor in Saos-2 osteosarcoma cells.

Özgür A. Özgür A. J Chemother. 2021 Dec;33(8):554-563. doi: 10.1080/1120009X.2021.1908650. Epub 2021 Apr 2. J Chemother. 2021. PMID: 33794753

8

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.

Goldman JW, Raju RN, Gordon GA, El-Hariry I, Teofilivici F, Vukovic VM, Bradley R, Karol MD, Chen Y, Guo W, Inoue T, Rosen LS. Goldman JW, et al. BMC Cancer. 2013 Mar 25;13:152. doi: 10.1186/1471-2407-13-152. BMC Cancer. 2013. PMID: 23530663 Free PMC article. Clinical Trial.

9

A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.

Thakur MK, Heilbrun LK, Sheng S, Stein M, Liu G, Antonarakis ES, Vaishampayan U, Dzinic SH, Li X, Freeman S, Smith D, Heath EI. Thakur MK, et al. Invest New Drugs. 2016 Feb;34(1):112-8. doi: 10.1007/s10637-015-0307-6. Epub 2015 Nov 18. Invest New Drugs. 2016. PMID: 26581400 Free PMC article. Clinical Trial.

10

A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma.

Goyal L, Wadlow RC, Blaszkowsky LS, Wolpin BM, Abrams TA, McCleary NJ, Sheehan S, Sundaram E, Karol MD, Chen J, Zhu AX. Goyal L, et al. Invest New Drugs. 2015 Feb;33(1):128-37. doi: 10.1007/s10637-014-0164-8. Epub 2014 Sep 24. Invest New Drugs. 2015. PMID: 25248753 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

84 results

Results by year